Patents Assigned to BioSynth S.r.l.
-
Patent number: 11576959Abstract: The present invention refers to new glycoconjugate antigens expressing built-in multiple epitopes and to polyvalent glycoconjugate vaccines intended for the protection of mammalians, and particularly for the protection of the human population from enteropathogenic bacteria, such as the Gram-positive anaerobic bacterium Clostridium difficile and the Gram-negative bacteria Salmonella typhi, Escherichia Coli, Vibrio Cholerae, Shigella flexneri, Salmonella typhimurium, Salmonella enteritidis, Salmonella paratyphi A, Shigella sonnei, Shigella dysenteriae, Salmonella cholerasuis, Klebsiella, Enterobacter, Pseudomonas aeruginosa and/or from viral gastrointestinal infections due to human noroviruses.Type: GrantFiled: January 25, 2021Date of Patent: February 14, 2023Assignee: BIOSYNTH S.R.L.Inventor: Massimo Porro
-
Patent number: 11547755Abstract: The present invention refers to new conjugate antigens expressing built-in multiple epitopes and to polyvalent glycoconjugate vaccines and formulations containing the same. In addition, the present invention concerns the use of these vaccines in particular for the protection of the human population, and in particular for the protection of the paediatric population from pulmonary and systemic infections due to S. pneumoniae, N. meningitidis, H. influenzae, K. pneumoniae, M. tuberculosis, S. aereus, or from intestinal infections due to S. typhi, V. cholerae and E. coli. The present invention additionally refers to new polyvalent glycoconjugate vaccines for the protection from C. albicans and E. coli systemic and genitourinary infections or for the protection from M. bovis infections in veterinary medicine.Type: GrantFiled: April 9, 2019Date of Patent: January 10, 2023Assignee: BIOSYNTH S.R.L.Inventor: Massimo Porro
-
Patent number: 11246919Abstract: The present invention refers to new glycoconjugate antigens expressing built-in multiple epitopes and to polyvalent glycoconjugate vaccines intended for the protection of mammalians, and particularly for the protection of the human population from enteropathogenic bacteria, such as the Gram-positive anaerobic bacterium Clostridium difficile and the Gram-negative bacteria Salmonella typhi, Escherichia coli, Vibrio cholerae, Shigella flexneri, Salmonella typhimurium, Salmonella enteritidis, Salmonella paratyphi A, Shigella sonnei, Shigella dysenteriae, Salmonella cholerasuis, Klebsiella, Enterobacter, Pseudomonas aeruginosa and/or from viral gastrointestinal infections due to human noroviruses.Type: GrantFiled: October 28, 2019Date of Patent: February 15, 2022Assignee: BIOSYNTH S.R.L.Inventor: Massimo Porro
-
Patent number: 11147872Abstract: The present invention refers to new conjugate antigens expressing built-in multiple epitopes and to polyvalent glycoconjugate vaccines and formulations containing the same. In addition, the present invention concerns the use of these vaccines in particular for the protection of the human population, and in particular for the protection of the paediatric population from pulmonary and systemic infections due to S. pneumoniae, N. meningitidis, H. influenzae, K. pneumoniae, M. tuberculosis, S. aureus, or from intestinal infections due to S. typhi, V. cholerae and E. coli. The present invention additionally refers to new polyvalent glycoconjugate vaccines for the protection from C. albicans and E. coli systemic and genitourinary infections or for the protection from M. bovis infections in veterinary medicine.Type: GrantFiled: April 9, 2019Date of Patent: October 19, 2021Assignee: BIOSYNTH S.R.L.Inventor: Massimo Porro
-
Patent number: 10500263Abstract: The present invention refers to new glycoconjugate antigens expressing built-in multiple epitopes and to polyvalent glycoconjugate vaccines intended for the protection of mammalians, and particularly for the protection of the human population from enteropathogenic bacteria, such as the Gram-positive anaerobic bacterium Clostridium difficile and the Gram-negative bacteria Salmonella typhi, Escherichia Coli, Vibrio Cholerae, Shigella flexneri, Salmonella typhimurium, Salmonella enteritidis, Salmonella paratyphi A, Shigella sonnei, Shigella dysenteriae, Salmonella cholerasuis, Klebsiella, Enterobacter, Pseudomonas aeruginosa and/or from viral gastrointestinal infections due to human noroviruses.Type: GrantFiled: July 24, 2015Date of Patent: December 10, 2019Assignee: BIOSYNTH S.R.L.Inventor: Massimo Porro
-
Patent number: 10300135Abstract: The present invention refers to new conjugate antigens expressing built-in multiple epitopes and to polyvalent glycoconjugate vaccines and formulations containing the same. In addition, the present invention concerns the use of these vaccines in particular for the protection of the human population, and in particular for the protection of the paediatric population from pulmonary and systemic infections due to S. pneumoniae, N. meningitidis, H. influenzae, K. pneumoniae, M. tuberculosis, S. aureus, or from intestinal infections due to S. typhi, V. cholerae and E. coli. The present invention additionally refers to new polyvalent glycoconjugate vaccines for the protection from C. albicans and E. coli systemic and genitourinary infections or for the protection from M. bovis infections in veterinary medicine.Type: GrantFiled: January 29, 2014Date of Patent: May 28, 2019Assignee: BIOSYNTH S.R.L.Inventor: Massimo Porro
-
Publication number: 20170143821Abstract: The present invention refers to new conjugate antigens expressing built-in multiple epitopes and to polyvalent glycoconjugate vaccines and formulations containing the same. In addition, the present invention concerns the use of these vaccines in particular for the protection of the human population, and in particular for the protection of the paediatric population from pulmonary and systemic infections due to S. pneumoniae, N. meningitidis, H. influenzae, K. pneumoniae, M. tuberculosis, S. aureus, or from intestinal infections due to S. typhi, V. cholerae and E. coli. The present invention additionally refers to new polyvalent glycoconjugate vaccines for the protection from C. albicans and E. coli systemic and genitourinary infections or for the protection from M. bovis infections in veterinary medicine.Type: ApplicationFiled: January 29, 2014Publication date: May 25, 2017Applicant: BIOSYNTH S.R. L.Inventor: Massimo PORRO
-
Patent number: 7588765Abstract: The present invention concerns a conjugation process for coupling a endotoxin (LPS) free polyfunctional polysaccharide with a polyfunctional carrier protein with quantitative yields. The invention also provides for vaccine formulations comprising the glyconjugate antigen manufactured by the process.Type: GrantFiled: May 7, 2003Date of Patent: September 15, 2009Assignee: Biosynth S.r.l.Inventor: Massimo Porro
-
Patent number: 6951652Abstract: A vaccine is disclosed which is useful for protecting a host from Gram negative infections and the effects of endotoxin, therefore preventing sepsis and septic shock. The vaccine is prepared by combining LPS free or in conjugate form with a stoichiometric excess of a peptide of the formula: (a) (A)n wherein A is Lysine or Arginine and n is an integer with a minimum value of 7; (b) (AB)m wherein A is Lysine or Arginine and B is a hydrophobic amino acid selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; m is an integer with a minimum value of 3; and (c) (ABC)p wherein A is a cationic amino acid which is Lysine or Arginine; B and C are hydrophobic amino acids which may be the same or different and are selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; p is an integer with a minimum value of 2.Type: GrantFiled: July 29, 1998Date of Patent: October 4, 2005Assignee: BioSynth S.r.l.Inventor: Massimo Porro
-
Patent number: 5834430Abstract: The present invention is concerned with methods of potentiating an antibiotic. The invention also includes compositions of an antibiotic and a peptide having units of the formula:(a) (A).sub.n wherein A is Lysine or Arginine and n is an integer with a minimum value of 7.(b) (AB).sub.m wherein A is Lysine or Arginine and B is a hydrophobic amino acid selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; m is an integer with a minimum value of 3; and(c) (ABC).sub.p wherein A is a cationic amino acid which is Lysine or Arginine; B and C are hydrophobic amino acids which may be the same or different and are selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; p is an integer with a minimum value of 2. The compositions have potentiated antibiotic activity.Type: GrantFiled: May 31, 1995Date of Patent: November 10, 1998Assignee: BiosYnth S.r.l.Inventors: Massimo Porro, Martti Varra
-
Patent number: 5652211Abstract: The present invention is concerned with a peptide composition which includes a peptide having units of the formula:(a) (A).sub.n wherein A is Lysine or Arginine and n is an integer with a minimum value of 7.(b) (AB).sub.m wherein A is Lysine or Arginine and B is a hydrophobic amino acid selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; m is an integer with a minimum value of 3; and(c) (ABC).sub.p wherein A is a cationic amino acid which Is Lysine or Arginine; B and C are hydrophobic amino acids which may be the same or different and are selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; p is an integer with a minimum value of 2. The compositions of the invention bind Lipid-A of endotoxins.Type: GrantFiled: July 26, 1993Date of Patent: July 29, 1997Assignee: BiosYnth S.r.l.Inventor: Massimo Porro
-
Patent number: 5589459Abstract: The present invention provides methods of using peptides of the formula R.sub.1 --(A--B--C).sub.n --R, wherein R.sub.1 and R are independently H or an amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys and Arg; B is an amino acid selected from the group consisting of Phe, Tyr, and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of 1-100. The peptides are used for the removal of endotoxin from blood or sera; the detoxification of bacterial endotoxin; and the prevention of the contamination of products with endotoxin.Type: GrantFiled: July 26, 1994Date of Patent: December 31, 1996Assignee: BiosYnth s.r.l.Inventor: Massimo Porro
-
Patent number: 5371186Abstract: The present invention provides novel peptides of the formula R.sub.1 -(A-B-C).sub.n -R, where R.sub.1 and R are independently H or an amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys, Arg, and His; B is an amino acid selected from the group consisting of Phe, Tyr, and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of 1-100. The peptides are used inter alia for the prevention and/or treatment of septic shock, for the detection of endotoxin and the preparation of antigenic complexes of Lipid A.Type: GrantFiled: January 16, 1992Date of Patent: December 6, 1994Assignee: Biosynth S.r.l.Inventor: Massimo Porro
-
Patent number: 5358933Abstract: Novel peptides are disclosed which are based on the formula:R.sub.1 (Lys-Phe-Leu).sub.n --Rwherein n is an integer of from 1-10 and R and R.sub.1 are H or an amino acid residue or a fatty acid residue which are useful in the treatment of septic shock.Type: GrantFiled: April 19, 1993Date of Patent: October 25, 1994Assignee: BiosYnth S.r.l.Inventor: Massimo Porro